The developed solid dispersion powder contains the drug at the concentration of 25% w/w, and thus the final concentration of the drug in tablets or capsules is approximately 10% w/w. Although we can prepare soft gel capsules using the developed oral solution, their drug concentration is just 0.13% w/w owing to the low solubility of the drug, which makes these capsules bigger than the solid dispersion formulations. The oral solution has other applications. For example, in human mass balance studies commonly performed during drug development, radioactively labeled drug substances are used to evaluate human ADME. However, creating a solid dispersion using labeled drug substances might be challenging owing to facility limitations. In this scenario, the oral solution may be helpful to overcome this limitation. Additionally, because the oral solution does not pose any risk in terms of content uniformity, it can also be employed in micro-dosing studies. In summary, we believe that developing multiple formulations that enhance absorption will increase the flexibility of ADME studies. This would facilitate rapid and efficient development of S-892216.